Navigation Links
Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
Date:9/28/2010

ure to product liability claims and product recalls and the possibility that Endo may not be able to adequately insure itself; the successful efforts of manufacturers of branded pharmaceuticals to use litigation and legislative and regulatory efforts to limit the use of generics and certain other products; Endo's ability to successfully implement its acquisition and in-licensing strategy; regulatory or other limits on the availability of controlled substances that constitute the active ingredients of some of its products and products in development; the availability of third-party reimbursement for Endo's products; the outcome of any pending or future litigation or claims by third parties or the government, and the performance of indemnitors with respect to claims for which Endo has been indemnified; Endo's dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of its total revenues; a determination by a regulatory agency that Endo is engaging or has engaged in inappropriate sales or marketing activities, including promoting the "off-label" use of its products, the risk that demand for and acceptance of Endo's products or services may be reduced; the risk of changes in governmental regulations; the impact of economic conditions; the impact of competition and pricing and other risks and uncertainties, including those detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in their annual reports on Form 10-K for the year ended December 31, 2009, which were filed with the Securities and Exchange Commission. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to diff
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14
(Date:7/26/2014)... 2014 “BRIC Sinuscopes Market Outlook to ... market. The report provides value, in millions of US ... dollars) within market segments – Rigid Non-Video Sinuscopes. , ... data for each of these market categories, and global ... and news and deals related to the Sinuscopes market ...
(Date:7/26/2014)... Dallas, TX (PRWEB) July 26, 2014 ... sclerosis or encephalomyelitis disseminata, is an inflammatory disease ... in the brain and spinal cord are damaged. ... the nervous system to communicate, resulting in a ... mental, and sometimes psychiatric problems. Multiple sclerosis takes ...
(Date:7/26/2014)... 26, 2014 According to the Metabolic ... is a comprehensive bodybuilding program that helps men lose ... anabolic steroids . The program also instructs men how ... , Vkool reveals in its review that this ... can help men get ripped and jacked at the ...
(Date:7/25/2014)... 26, 2014 Dental Perfection, a Derby ... services including general dentistry, clear braces and much more, ... this year in Derby. The new practice, which is ... Medical Centre in Littleover, Derby. Patients may already pre-register ... The new dental practice, which is headed by Invisalign ...
(Date:7/25/2014)... 26, 2014 According to a ... by Product (vibration monitoring, thermography, ultrasound emission, lubricating ... Component, Application and Geography - Global Forecast to ... health monitoring market is expected to reach $2.50 ... 2020. , Browse 117 market data Tables and ...
Breaking Medicine News(10 mins):Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
... According to a study published in the October issue of ... phyllodes tumors rare breast malignancies accounting for 0.5 to ... more prevalent in Hispanic patients. Population-based estimates indicate that the ... women, with the highest frequencies in Hispanic women. Previous ...
... Whistleblowing incidents can have a serious, long-term impact on ... a responsibility to provide them with the support they ... of the Journal of Clinical Nursing . ... nurses who had been reported by whistleblowers. ...
... cancer survivors in Northern Ireland suffer from physical and ... according to new research from Macmillan Cancer Support and ... its kind in Northern Ireland, also found cancer survivors ... services than the general population. The research highlighted ...
... partnership with the American Society for Radiation Oncology (ASTRO), ... recognized 39 educators with the 2011 Educator of the ... the Year Award to recognize outstanding teachers and mentors ... programs were given the opportunity to select one faculty ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Oct. ... as multivitamins, minerals and folic acid may actually raise the ... new study suggests. Dietary supplements are widely used in ... disease. However, the long-term health consequences of many compounds are ...
... conclusions can be drawn about the effect of recent reforms ... coalition government,s proposals to extend competition, warn experts on ... Skellern at the London School of Economics and Political Science ... of hospital competition on quality of care within the English ...
Cached Medicine News:Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Greater support is needed to tackle the serious emotional consequences of whistleblowing 2Health News:Greater support is needed to tackle the serious emotional consequences of whistleblowing 3Health News:Almost half of cancer survivors have ill health in later years 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Dietary Supplements May Harm Older Women: Study 2Health News:Dietary Supplements May Harm Older Women: Study 3Health News:Experts question merits of extending competition to improve hospital care 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: